To evaluate the effects of oral nanocurcumin in levels of micro-RNA expression and Th17 cell development factors in patients with ankylosing spondylitis, patients with clinical symptoms and radiographic results of spine, who their disease diagnosed by rheumatologist be referred to the person in charge of research. Then the study and its objectives and complements that are used and possible complications will be explained to the patient. In this study, after receiving written the questionnaire and obtaining the necessary information and history will be recorded. Then 8 cc of fasting blood will be taken from each patient. Patients randomly block (block randomization) in the control group (n=12) and supplements (n=12) are placed. The supplement group, will receive 80 mg nanocurcumin and the control group will receive placebo. During the 4-month period of study patients will take capsule daily. In the end of study , 8 cc of fasting blood will be taken from patients who received nanocurcumin and placebo and then will be completed questionnaires and obtaining the necessary information.
General information
Acronym
AS
IRCT registration information
IRCT registration number:IRCT2017052927520N7
Registration date:2017-06-13, 1396/03/23
Registration timing:registered_while_recruiting
Last update:
Update count:1
Registration date
2017-06-13, 1396/03/23
Registrant information
Name
Mehdi Yousefi
Name of organization / entity
Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
Country
Iran (Islamic Republic of)
Phone
+98 41 3336 4665
Email address
yousefime@tbzmed.ac.ir
Recruitment status
Recruitment complete
Funding source
Tabriz University of Medical Sciences
Expected recruitment start date
2017-05-07, 1396/02/17
Expected recruitment end date
2017-07-08, 1396/04/17
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
The effects of oral nanocurcumin on expression levels of microRNA and Th17 cells development factors in ankylosing spondylitis patients
Public title
Oral nanocurcumin and treatment of ankylosing spondylitis
Purpose
Health service research
Inclusion/Exclusion criteria
Inclusion Criteria:
Willingness to cooperate; ranging in age 28 to 51 years; diagnosis of ankylosing spondylitis by rheumatologist; patients with a BASDAI > 4 as having active disease; disease duration 5-8 years.
Exclusion Criteria:
Use of nutritional supplements and antioxidant and immunosuppressive drugs alpha-lipoic acid a month before the study; pregnancy and lactation; history of diabetes and other chronic diseases; history of other autoimmune diseases; corticosteroid use during illness; acceptance rate of less than 70% of supplements; not wanting to continue cooperation.